drugset / Trial / NCT00669942
Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients
RandomizedParallel-groupDouble-blindBasic science
Summary
Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Secukinumab | Monoclonal antibody | 10 mg/kg | Intravenous |